141 related articles for article (PubMed ID: 19910069)
1. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
2. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
[TBL] [Abstract][Full Text] [Related]
5. Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach.
Ng WH; Soo KC; Huynh H
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338842
[TBL] [Abstract][Full Text] [Related]
6.
Lee GW; Hur W; Kim JH; Park DJ; Kim SM; Kang BY; Sung PS; Yoon SK
Anticancer Res; 2021 Apr; 41(4):1883-1893. PubMed ID: 33813393
[TBL] [Abstract][Full Text] [Related]
7. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
Feng J; Lu PZ; Zhu GZ; Hooi SC; Wu Y; Huang XW; Dai HQ; Chen PH; Li ZJ; Su WJ; Han CY; Ye XP; Peng T; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Jan; 42(1):160-170. PubMed ID: 32541921
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma.
Jiang C; Xu R; Li XX; Zhou YF; Xu XY; Yang Y; Wang HY; Zheng XFS
Mol Cancer Ther; 2018 Dec; 17(12):2610-2621. PubMed ID: 30224431
[TBL] [Abstract][Full Text] [Related]
9. Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway.
Sun L; He M; Li F; Wu D; Zheng P; Zhang C; Liu Y; Liu D; Shan M; Yang M; Ma Y; Lian J; Xiong H
Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38573832
[TBL] [Abstract][Full Text] [Related]
10. Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma.
Scheau C; Badarau IA; Caruntu C; Mihai GL; Didilescu AC; Constantin C; Neagu M
Molecules; 2019 Jun; 24(13):. PubMed ID: 31247901
[TBL] [Abstract][Full Text] [Related]
11. ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1.
Wang K; Qiu X; Zhang Z; Xu H; Tan Y; Su R; Gao F; Zhuo J; Li W; Lian Z; He H; Xu X
Cell Commun Signal; 2023 Aug; 21(1):193. PubMed ID: 37537668
[TBL] [Abstract][Full Text] [Related]
12. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
Smith MP; Ferguson J; Arozarena I; Hayward R; Marais R; Chapman A; Hurlstone A; Wellbrock C
J Natl Cancer Inst; 2013 Jan; 105(1):33-46. PubMed ID: 23250956
[TBL] [Abstract][Full Text] [Related]
13. ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line.
Deming D; Geiger P; Chen H; Vaccaro A; Kunnimalaiyaan M; Holen K
J Gastrointest Surg; 2008 May; 12(5):852-7. PubMed ID: 18299943
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts.
Xin H; Wang K; Hu G; Xie F; Ouyang K; Tang X; Wang M; Wen D; Zhu Y; Qin X
PLoS One; 2014; 9(1):e85308. PubMed ID: 24416385
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor CLCA1 inhibits angiogenesis via TGFB1/SMAD/VEGF cascade and sensitizes hepatocellular carcinoma cells to Sorafenib.
He J; Wu F; Li J; Deng Q; Chen J; Li P; Jiang X; Yang K; Xu S; Jiang Z; Li X; Jiang Z
Dig Liver Dis; 2024 Jan; 56(1):176-186. PubMed ID: 37230858
[TBL] [Abstract][Full Text] [Related]
16. Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice.
Wentz SC; Wu H; Yip-Schneider MT; Hennig M; Klein PJ; Sebolt-Leopold J; Schmidt CM
J Gastrointest Surg; 2008 Jan; 12(1):30-7. PubMed ID: 17987349
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats.
Chu TH; Chan HH; Hu TH; Wang EM; Ma YL; Huang SC; Wu JC; Chang YC; Weng WT; Wen ZH; Wu DC; Chen YA; Tai MH
Cancer Med; 2018 Jun; 7(6):2567-2580. PubMed ID: 29683262
[TBL] [Abstract][Full Text] [Related]
18. Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology.
Yu JX; Craig AJ; Duffy ME; Villacorta-Martin C; Miguela V; Ruiz de Galarreta M; Scopton AP; Silber L; Maldonado AY; Rialdi A; Guccione E; Lujambio A; Villanueva A; Dar AC
Mol Cancer Ther; 2019 Sep; 18(9):1506-1519. PubMed ID: 31213506
[TBL] [Abstract][Full Text] [Related]
19. Targeting insulin-like growth factor axis in hepatocellular carcinoma.
Wu J; Zhu AX
J Hematol Oncol; 2011 Jul; 4():30. PubMed ID: 21729319
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.
Da X; Cao B; Mo J; Xiang Y; Hu H; Qiu C; Zhang C; Lv B; Zhang H; He C; Yang Y
BMC Cancer; 2024 Feb; 24(1):273. PubMed ID: 38409035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
